CLDN15 and osteosarcoma: Importantly, NMD is particularly pronounced in osteosarcomas, and the absence of adequate cell-to-cell adhesions (e.g., CLDN1, CLDN15) and a potent host immune response, makes vitamin D3 a likely candidate for combined immunotherapy (14–17).